Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells

Figure 5 Assessment of the mitochondrial membrane potential in HepG2 living cells after siRNA transfection and treatment with an agonistic anti-Fas antibody or doxorubicin (Dox). In four to five different experiments, the percentage (mean ± SE) of cells with a low mitochondrial membrane potential was 4.5 ± 1.3% in C cells, 7.7 ± 2.9% in the Be- cells, 29.1 ± 4.9% in C cells treated with the Fas Ab, 52.5 ± 7.1% in Be- cells treated with the Fas Ab (P < 0.05 vs treated C cells), 23.6 ± 3% in C cells treated with Dox, and 38.8 ± 3.8% in Be- cells treated with Dox (P < 0.05 vs treated C cells).